References
- Kaitin KI. (1998). Global drug development and international harmonization: the emergence of China as a world pharmaceutical player. Drug Inform J 32:1187S–1191S.
- Li CJ, Chen DY, Chen KX. (2004). Current status of drug discovery and development in China. Chin Bull Life Sci 16:324–329.
- Liang Y, Liu L, Lu S, Xie L, Kang A, Xie T, Xie Y, Sheng L, Liu X, Wang GJ. (2009). Application of a hybrid ion trap/time-of-flight mass spectrometer in metabolite characterization studies: structural identification of the metabolism profile of antofloxacin in rats rapidly using MSn information and accurate mass measurements. J Pharm Biomed Anal 50:1022–1025.
- Lin HY, Shen HL. (2006). Antibiotics clinical usage in general hospital. Chin J Nosocomial 16:681–683.
- Lode H, Borner K, Koeppe P. (1998). Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27:33–39.
- Meibohm B, Derendorf H. (2002). Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci 91:18–31.
- Schaefer HG, Ahr G, Kuhlmann J. (1995). Pharmacokinetic development of quinolone antibiotics. Int J Clin Pharmacol Ther 33:266–276.
- Tayab ZR, Hochhaus G, Kaufmann S, Jäger D, Barth J. (2006). Do intensive care patients need an individualized dosing regimen for levofloxacin? Int J Clin Pharmacol Ther 44:262–269.
- Wang J, Xiao Y, Huang W, Xu N, Bai C, Xiu Q, Mei C, Zheng Q. (2010a). A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections. Chemotherapy 56:378–385.
- Wang J, Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Liang J, Zhang M, Li T. (2010b). Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-dose intravenous administration in healthy Chinese male volunteers. Xenobiotica 40:344–349.
- Xiao XM, Xiao YH. (2008). Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection. Acta Pharmacol Sin 29:1253–1260.
- Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M, Li T. (2008a). Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers. Biopharm Drug Dispos 29:167–172.
- Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T, Liu Y, Xia Y. (2008b). Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers. Int J Clin Pharmacol Ther 46:172–179.
- Ye H, Wu JM, Yang YS, Chen KX, Ji RY. (2002). Antibacterial activities of the derivatives—YH54 and Yh57 of levofloxacin in vitro. Chin Pharmacol Bull 18:112–113.
- Zhu Q, Liao J, Xie L, Wang GJ, Liu XD. (2009). Mechanism-based inhibition of CYP1A2 by antofloxacin, an 8-NH2 derivative of levofloxacin in rats. Xenobiotica 39:293–301.